Protein synthesis inhibition is a highly successful target for developing clinically effective and safe antibiotics. There are several targets within the ribosomal machinery, and small ribosomal protein S4 (RPSD) is one of the newer targets. Screening of microbial extracts using antisense-sensitized rpsD Staphylococcus aureus strain led to isolation of okilactomycin and four new congeners from Streptomyces scabrisporus. The major compound, okilactomycin, was the most active, with a minimum detection concentration of 3-12 lg ml À1 against antisense assay, and showed an MIC of 4-16 lg ml À1 against Gram-positive bacteria, including S. aureus. The congeners were significantly less active in all assays, and all compounds showed a slight preferential inhibition of RNA synthesis over DNA and protein synthesis. Antisense technology, due to increased sensitivity, continues to yield new, even though weakly active, antibiotics.
INTRODUCTION
Bacterial resistance to antibiotics continues to increase and is reaching alarming levels for certain organisms, including methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, and remains a serious threat to human lives. 1 The current clinically used antibiotics target fewer than 25 molecular targets, including a number of proteins of ribosomal targets in the protein synthesis machinery. Inhibition of protein synthesis is one of the most highly effective and proven antibacterial approaches. 2, 3 Protein synthesis is catalyzed by a ribosome that is comprised of two asymmetric macromolecular units, the large (50S) and small (30S) subunits. The small subunit is composed of 16S rRNA and 21 r-proteins, S1-S21 (refs 4-6) . Ribosomal proteins are known to help the ribosome to maintain its quaternary structure. Most of the clinically used drugs bind not only to rRNA but also to one or more ribosomal proteins, and the inhibition of protein synthesis is the composite result of disturbances due to both interactions. Alteration of rRNA binding to r-proteins inactivates protein synthesis. Therefore, selectively altering the conformation of a particular r-protein, or inhibiting the synthesis of an r-protein, would result in loss of function, and may lead to inhibition of the bacterial protein synthesis. Small ribosomal protein S4 (RPSD) is one of those proteins that seemed to be suitable targets for antibacterial discovery. It is encoded by the rpsD gene in both Gram-positive and Gram-negative bacteria, is conserved across bacterial species and is essential for bacterial growth. 7, 8 A S. aureus-based antisense two-plate whole-cell differential sensitivity screening assay was designed earlier and developed by us for the discovery of new antibiotics. 9, 10 This assay was based on an antisense-sensitized S. aureus strain that targeted the fabF/H genes, leading to reduced expression and thus reduced production of FabF/H proteins. 9, 10 This assay led to the discovery of platensimycin and platencin, two novel and potent inhibitors of FabF and FabF/H enzymes with in vivo antibiotic activities. [11] [12] [13] [14] A similar two-plate assay, with reduced expression of the rpsD gene by antisense and hence reduced expression of the RPSD protein, was developed and used for screening of natural product extracts. This screening strategy led to the identification of lucensimycin A and B 15 from a strain of Streptomyces lucensis MA7349, coniothyrione from a fungal strain of Coniothyrium cerealis MF7209 (ref. 16) , pleosporone from an unidentified ascomycete 17 and phaeosphenone from Phaeosphaeria sp. 18 Continued screening of microbial extracts led to the discovery of a Streptomyces scabrisporus strain that showed good activity in the two-plate screening assay. The acetone extract of the fermentation broth produced by the strain was subjected to bioassay-guided fractionation, leading to the isolation of okilactomycin (1) and four new compounds, named okilactomycin A (2), B (3), C (4) and D (5) (Figure 1 ). The isolation, structure elucidation and biological characterization of these compounds are reported herein.
RESULTS AND DISCUSSION

Fermentation and isolation
The producing organism was recovered from a soil sample collected in Costa Rica. The strain was characterized using morphological, chemotaxonomic and molecular identification (16S rDNA sequencing) methods, and was identified taxonomically as a new strain of S. scabrisporus. The strain was grown in millet, pharmamedia, glucose (MPG) liquid medium in a shake flask for 13 days.
The fermentation broth was extracted with equal volume of acetone, and the extract was concentrated to remove most of the acetone and chromatographed on Amberchrome polystyrene resin. The pooled biologically active fractions were chromatographed by reversed-phase HPLC to yield the known okilactomycin (1) (9.3 mg, 37.2 mg l À1 ), and novel okilactomycins A (2) (5.7 mg, 15.2 mg l À1 ), B (3) (0.8 mg, 2.1 mg l À1 ), C (4) (4.2 mg, 11.2 mg l À1 ) and D (5) (0.6 mg, 0.6 mg l À1 ).
Structure elucidation
Compound 1 exhibited a molecular weight of 416 atomic mass units (amu), with the molecular formula C 24 H 32 O 6 (high resolution electrospray ionization fourier transform mass spectrometry (HRESIFTMS)), and was identified as okilactomycin by comparing with spectroscopic data ( 1 H, 13 19 This structure was originally determined by X-ray crystallographic studies and was recently confirmed by asymmetric total synthesis of the unnatural opposite enantiomer. 20 ) and H-21; and H-9 to H-21 indicated that they were present on the same a-face of the molecule. The NOESY correlations of H-7 to H-5 and H-22 indicated that they were present on the opposite face of the molecule. The NOESY correlations of pseudo-axial H-14a (d H 1.82) to H-3b (d H 1.62) confirmed the configuration at the spiro center, C-13. H-14a also showed a large coupling (J¼10.6 Hz) with H-15, indicating a diaxial coupling and thus placing the C-19 methyl group at the pseudo-equatorial orientation in the pseudo-chair conformation of the spiro-fused cyclohexene ring. On the basis of these data, structure 2 was assigned for okilactomycin A (2).
Okilactomycin B (3) was assigned a molecular formula of C 27 Discovery of okilactomycin and congeners C Zhang et al absorption bands characteristic of conjugated ketones (n max ¼1700 and 1631 cm À1 ). The 13 C NMR spectrum ( 21 .2) indicated differences between the two compounds. The proton and carbon chemical shifts of C-17 shifted significantly upfield due to the absence of conjugation. The key HMBC correlations of H-17 to C-18; and H 3 -18 to C-15, C-16 and C-17 confirmed structure 5 for okilactomycin D.
Biological activities
All five compounds were first evaluated in the S. aureus antisense rpsD-sensitized two-plate differential sensitivity assay. Okilactomycin showed the most potent activity in this assay and displayed a 20-mm zone of clearance at 62 mg ml À1 on the antisense plate and 13 mm on the control plate. The zone of clearance was concentration dependent and was measured by twofold dilution. At 12.5, 6.25 and 3.13 mg ml À1 , compound 1 showed 15, 13 and 11 mm zones of clearance on the antisense plate but no activity on the control plate. This indicated No. Discovery of okilactomycin and congeners C Zhang et al a minimum detection concentration (MDC) of 3-12.5 mg ml À1 . Okilactomycins A-D were less active than okilactomycin. Of these four, okilactomycin A (2) showed the best activity with an MDC of 31-62 mg ml À1 . Okilactomycins B (3), C (4) and D (5) showed MDC values of 250, 250 and 500 mg ml À1 , respectively. The most potent compound okilactomycin (1) exhibited an MIC of 8-16 mg ml À1 against S. aureus (Table 3) . Compound 1 inhibited growth of Streptococcus pneumoniae (MIC of 8-16 mg ml À1 ), Enterococcus faecalis (MIC of 16 mg ml À1 ) and Bacillus subtilis (MIC of 4-16 mg ml À1 ). MIC data observed in this study are consistent with that reported earlier. 21 Compound 1 did not show activity against Gram-negative bacteria, but did inhibit growth of the Escherichia coli (envA/tolC) strain, which harbors mutated membrane and efflux pump, and showed an MIC of 64 mg ml À1 . The other four compounds were significantly less active in this assay with only 5 showing a weak activity against S. pneumoniae and also E. coli. No clear conclusion about SAR could be drawn due to weak activity.
Mechanistically, compounds 1, 2 and 4 showed preferential inhibition of RNA synthesis compared with DNA and protein synthesis (Figure 2a) . These data are similar to the data observed for two other RPSD active compounds, pleosporone and phaeosphenone, identified by this assay. The other two compounds (3 and 5) showed o50% inhibition at 100 mg ml À1 (data not shown). This phenomenon requires further study to determine why RPSD-selective compounds in the antisense assay tend to selectively inhibit RNA synthesis rather than protein synthesis.
In conclusion, antisense screening method continue to aid the discovery of novel antibiotics, even though with weak activity, as illustrated by the discovery of okilactomycin and its new congeners, okilactomycins A-D (2-5). The most abundant compound 1 remains the most active compounds in this family.
EXPERIMENTAL PROCEDURE General experimental procedures
An Agilent HP1100 was used for analytical HPLC. Optical rotations were measured on a Perkin-Elmer 241 (Waltham, MA, USA) Polarimeter. UV spectra were recorded in MeOH on a Beckman (Fullerton, CA, USA) DU-70 Spectrophotometer. IR spectra were recorded on a Perkin-Elmer Spectrum One spectrometer. High resolution electrospray inonization mass spectrum (HRESIMS) were obtained on a Thermo Quest (Boston, MA, USA) FTMS spectrometer using electrospray ionization. The NMR spectra were recorded on a Varian (Palo Alto, CA, USA) INOVA 500 FT-NMR spectrometer at 500 MHz for 1 H and 125 MHz for 13 
Microbial isolation conditions
The strain F-117,187 was isolated from soil collected in Costa Rica, at the INBio Biodiversity Garden, from a coffee tree plantation area. This soil was air dried and suspended in sterile water. The soil suspension was serially diluted, plated on selective isolation media and incubated at 28 1C for at least 6 weeks. The strain was isolated from an NZ-amine-based agar medium containing nalidixic acid (20 mg ml À1 ). The colony was purified on Yeast Extract Malt Extract Glucose medium (ISP2) and preserved as frozen agar plugs in 10% glycerol. Discovery of okilactomycin and congeners C Zhang et al
Characterization of the S. scabrisporus strain
Sporulating characters were observed upon growth of the strain on different selective media after 21 days incubation at 28 1C. The strain grows abundantly with extensive development of a gray to grayish brown aerial mycelium on media ISP2, ISP3, ISP5 and ISP7. It exhibited sparse growth and poor aerial development on medium ISP4. Microscopically, the strain produced long chains of spores as open coils or as loops formed at the end of the aerial hyphae. Good sporulation was observed on media ISP2, ISP3, ISP4 and ISP7 but no spore chains were formed on ISP5. This macro-and micromorphology are characteristic of members of the family Streptomycetaceae. Whole-cell major fatty acids were branched components iso-C 16:0 (29%), iso-C 16:1 H (10%), unsaturated components C 16:1 o7c (15%) and anteiso-C 15:0 (3.9%). The strain is characterized by good growth on glucose and rhamnose as the sole carbon source and exhibits limited growth on fructose, xylose, raffinose and inositol.
No growth was observed on arabinose, cellulose, saccharose or mannitol.
16S rDNA sequencing and phylogenetic analysis
Total genomic DNA from the producing strain was isolated and purified using the MasterPure Gram-Positive DNA Purification Kit (Epicentre Biotechnologies, Madison, WI, USA). PCR primers fD1 and rP2 22 were used for amplifying the 16S rRNA genes of the strain. The 1500 bp PCR products were purified and used as a template in sequencing reactions using the primers fD1 and rP2, 22 and 1100R and 926F. 23 Amplified DNA fragments were sequenced using the ABI PRISMDYE Terminator Cycle sequencing Kit and fragments were resolved using the ABI3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA). Partial sequences were assembled using the contig editor component of GeneStudio Professional sequence analysis software (GeneStudio Inc., Suwanee, GA, USA). Almost complete 16S rDNA sequence was aligned with representative sequences of Streptomyces and related species as identified with BLAST searches. The phylogenetic analysis, based on the Neighbor-Joining method using matrix pairwise comparisons of sequences corrected with Jukes and Cantor algorithm, 24, 25 shows that the strain is closely related to the strain type S. scabrisporus NBRC 100760 T . The strains share 100% sequence identity and this relatedness is well supported in the analysis by the bootstrap value (100%). All data suggest that strain F-117,187 can be identified as a new member of the species S. scabrisporus.
Production conditions
A seed culture of the strain was prepared by inoculation from a frozen vial containing agar plugs in a 50-ml Environmental Protection Agency (EPA) tube containing 10 ml of seed medium (in g agitation and 70% humidity for 13 days. Production in flasks was obtained transferring 2.5 ml of the inoculum from EPA tube to a 250-ml flask containing 50 ml of the same production medium, and the culture was incubated at 28 1C for 13 days in a rotary shaker at 220 r.p.m. and 70% humidity.
Extraction and isolation
A total of 40 flasks were harvested, pooled (B1 l) and extracted with 1 l acetone by shaking on a platform shaker for 60 min. The acetone extract was concentrated under reduced pressure to remove most of the acetone leaving behind mostly aqueous solution (B1 l), which was fractionated on an Amberchrome column, and eluted with a 100-min linear gradient of aqueous MeOH at a flow rate of 10 ml min À1 . These fractions were tested for their biological activity in the antisense rpsD two-plate assay. The fractions eluted with 52, 64, 78 and 90% aqueous MeOH possessed all of the biological activities. A 25% aliquot of the Amberchrome fractions eluted with 78% aqueous MeOH was chromatographed by reversed-phase HPLC using an Atlantis C 18 (10Â250 mm) column that was eluted with a 40-min gradient of 20-95% aqueous CH 3 CN containing 0.1% TFA at a flow rate of 5 ml min À1 . The fraction eluting at 28 min showed activity and was lyophilized to yield 9.3 mg (37.2 mg l À1 ) of okilactomycin (1) as an amorphous powder.
A similar 25% aliquot of the Amberchrome fraction eluted with 64% aqueous MeOH was fractionated by reversed-phase HPLC using a Zorbax C 8 (21.2Â250 mm) column that was eluted with a 40-min gradient of 40-50% aqueous CH 3 CN containing 0.1% TFA at a flow rate of 10 ml min À1 . Lyophilization of the active fractions eluting at 20 and 33 min yielded 0.8 mg (2.1 mg l À1 ) and 5.7 mg (15.2 mg l À1 ) of okilactomycins B (3) and A (2), respectively, as colorless gums.
Similarly, 25% aliquot of the Amberchrome fraction eluted at 52% aqueous MeOH was further chromatographed on Zorbax C 8 (21.2Â250 mm) column that was eluted with a 40-min gradient of 10-55% aqueous CH 3 CN containing 0.1% TFA at a flow rate of 10 ml min À1 . Fractions eluting at 38 min showed activity and was lyophilized to furnish 4.2 mg (11.2 mg l À1 ) of okilactomycin C (4) as a colorless gum.
Reversed-phase HPLC of the Amberchrome fraction eluted with 90% aqueous MeOH using Zorbax C 8 (21.2Â250 mm) column and eluted for 40 min with 45% aqueous CH 3 CN containing 0.1% TFA followed by a 10-min gradient of 45-95% aqueous CH 3 CN at a flow rate of 10 ml min À1 , and lyophilization of the active fraction eluting at 69 min yielded 0.6 mg (0.6 mg l À1 ) of okilactomycin D (5) . Okilactomycins B and C showed o50% inhibition of DNA, protein and RNA at 100 mg ml À1 , therefore the data are not shown.
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